Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study

@article{DeVito2020ComplianceWL,
  title={Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study},
  author={Nicholas J. DeVito and Seb Bacon and Ben Goldacre},
  journal={The Lancet},
  year={2020},
  volume={395},
  pages={361-369}
}
BACKGROUND Failure to report the results of a clinical trial can distort the evidence base for clinical practice, breaches researchers' ethical obligations to participants, and represents an important source of research waste. The Food and Drug Administration Amendments Act (FDAAA) of 2007 now requires sponsors of applicable trials to report their results directly onto ClinicalTrials.gov within 1 year of completion. The first trials covered by the Final Rule of this act became due to report… Expand
Clinical trial reporting: compliance with US rules is poor and not improving, study finds
Only 41% of clinical trials reported their results to the US clinical trials registry within a year of completion as required by law, a study has found. Researchers from Oxford University, UK, whoExpand
Clinical trial reporting performance of thirty UK universities on ClinicalTrials.gov—evaluation of a new tracking tool for the US clinical trial registry
TLDR
Assessment of whether the thirty UK universities receiving the most Medical Research Council funding in 2017–2018 complied with World Health Organization best practices for clinical trial reporting on the US Clinical Trial Registry suggests that UK universities often fail to update their data adequately on ClinicalTrials.gov. Expand
Transparency of results reporting for depression treatment studies in ClinicalTrials.gov: a cross-sectional study
TLDR
Characteristics of the transparent reporting of depression treatment studies registered in ClinicalTrials.gov were examined, finding that studies with any results were more likely to have hypotheses, include drug treatment conditions, and to have publications related to the study. Expand
Assessment of Trends in the Design, Accrual, and Completion of Trials Registered in ClinicalTrials.gov by Sponsor Type, 2000-2019
TLDR
The findings suggest that the composition and design of trials changed between 2000 and 2019 and differed substantially by sponsor type; increased funding toward larger randomized clinical trials may be warranted to inform clinical decision-making and guide future research. Expand
Poor compliance of clinical trial registration among trials included in systematic reviews: a cohort study.
TLDR
Although some improvement in clinical trial registration has been observed in recent years, the proportion of registered clinical trials included in recently published systematic reviews remains less than desirable. Expand
Investigator initiated trials versus industry sponsored trials - translation of randomized controlled trials into clinical practice (IMPACT)
TLDR
IITs funded by governmental bodies in Germany reached an impact that is comparable to international IITs and ISTs, and international ISTs less often gained impact by inclusion in systematic reviews or guidelines than I ITs. Expand
Study design, result posting and publication of late-stage cardiovascular trials.
TLDR
Interventional, late-phase cardiovascular disease studies in adults registered in Clinicaltrials.gov were searched for, and industry sponsors were more likely to invest in research on patent-protected drugs and devices than were non-industry sponsors. Expand
Gastroenterology Clinical Trials Transparency: An Analysis of Publication Rates From the ClinicalTrials.gov Database.
TLDR
Improvement of clinical trial transparency is needed in gastroenterology by ensuring consistency in reporting of results to the database or in publication form. Expand
Editorial Comment.
  • R. Boris
  • Medicine
  • The Journal of urology
  • 2021
TLDR
12 years of data on urology trial registration is evaluated to investigate early discontinuation, reported results and publication rates and highlights discrepancies between effort and results when it comes to clinical trials in urology. Expand
Registration of phase 3 crossover trials on ClinicalTrials.gov
TLDR
The registration and reporting of randomized crossover trials must account for the paired nature of the design, and observations and recommendations informed the development of guidelines for good reporting practices. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 40 REFERENCES
Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study
TLDR
Examination of compliance with mandatory reporting of summary clinical trial results on ClinicalTrials.gov found most trials subject to mandatory reporting did not report results within a year of completion. Expand
Compliance with results reporting at ClinicalTrials.gov.
TLDR
Despite ethical and legal obligations to disclose findings promptly, most HLACTs did not report results to ClinicalTrials.gov in a timely fashion during the study period, and industry-funded trials adhered to legal obligations more often than did trials funded by the NIH or other government or academic institutions. Expand
Reporting Discrepancies Between the ClinicalTrials.gov Results Database and Peer-Reviewed Publications
TLDR
Assessment of the consistency of results reported in the ClinicalTrials.gov results database compared with those summarized in peer-reviewed journal publications suggested validity problems in 1 or both sources. Expand
Clinical trial transparency: a reassessment of industry compliance with clinical trial registration and reporting requirements in the United States
TLDR
A reassessment of a 2015 cross-sectional analysis reported that pharmaceutical industry compliance with clinical trial registration and results reporting requirements under US law was suboptimal found that industry Compliance with US statutory disclosure requirements for the 15 reviewed drugs was consistently high. Expand
Clinical trial registration and reporting: a survey of academic organizations in the United States
TLDR
Before the compliance date for The Final Rule, some academic organizations had policies and resources that facilitate clinical trial registration and reporting, and most organizations appear to be unprepared to meet the new requirements. Expand
Compliance with requirement to report results on the EU Clinical Trials Register: cohort study and web resource
TLDR
To ascertain compliance rates with the European Commission’s requirement that all trials on the EU Clinical Trials Register post results to the registry within 12 months of completion, extensive evidence was found of errors, omissions, and contradictory entries in EUCTR data that prevented ascertainment of compliance for some trials. Expand
Linking ClinicalTrials.gov and PubMed to Track Results of Interventional Human Clinical Trials
TLDR
The study shows that even when combining publications and registry results, and despite availability of several information channels, trial sponsors do not sufficiently meet the mandate to inform the public either via a linked result publication or basic results submission. Expand
Clinical Trials Registration and Results Information Submission. Final rule.
  • Medicine
  • Federal register
  • 2016
TLDR
The requirements apply to the responsible party (meaning the sponsor or designated principal investigator) for certain clinical trials of drug products and device products that are regulated by the Food and Drug Administration (FDA) and for pediatric postmarket surveillances of a device product that are ordered by FDA. Expand
FDAAA TrialsTracker: A live informatics tool to monitor compliance with FDA requirements to report clinical trial results
TLDR
The FDAAA TrialsTracker is an online tool which publicly monitors compliance with results reporting requirements, facilitates open public audit, and promotes accountability and argues tools such as the authors' providing live data on trial reporting - can improve accountability and performance. Expand
Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study
TLDR
The enactment of FDAAA was followed by significantly higher proportions of trials that were registered and reporting results on ClinicalTrials.gov and significantly lower degrees of publication bias among trials supporting recent FDA approval of drugs for neuropsychiatric indications. Expand
...
1
2
3
4
...